Clinical Trial Update: Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating initiation of a PCSK9 inhibitor before percutaneous coronary intervention in acute myocardial infarction patients; the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• PCSK9 inhibitor (PCSK9 inhibitor)

Snippet

Sponsor: The Affiliated Hospital of Xuzhou Medical University | Conditions: Acute Myocardial Infarction (AMI) | Phase 4 | Status: NOT_YET_RECRUITING